A double-blind, placebo-controlled trial of modafinil (200 mg/day) for methamphetamine dependence.
AIM: To examine the safety and efficacy of modafinil (200 mg/day) compared to placebo in the treatment of methamphetamine dependence and to examine predictors of post-treatment outcome. PARTICIPANTS AND DESIGN: Eighty methamphetamine-dependent subjects in Sydney, Australia were allocated randomly to...
| Publicado en: | Addiction Vol. 104; no. 2; pp. 224 - 234 |
|---|---|
| Autores principales: | , , , , , , , , , |
| Formato: | clinical trial research tables/charts Journal Article |
| Publicado: |
Wiley-Blackwell
Feb2009
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105629762&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 105629762 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 09652140 AIO jtl: Addiction issn: 09652140 maglogo: Y pubinfo: dt: Feb2009 vid: 104 iid: 2 pid: 480 pub: Wiley-Blackwell place: Malden, Massachusetts artinfo: ui: 105629762 105629762 2010169904 10.1111/j.1360-0443.2008.02437.x NLM19149817 105629762 ppf: 224 ppct: 10 formats: fmt: @attributes: type: P tig: atl: A double-blind, placebo-controlled trial of modafinil (200 mg/day) for methamphetamine dependence. aug: au: Shearer J Darke S Rodgers C Slade T van Beek I Lewis J Brady D McKetin R Mattick RP Wodak A affil: National Drug and Alcohol Research Centre, University of New SouthWales, Sydney, NSW, Australia sug: subj: Modafinil Administration and Dosage Modafinil Therapeutic Use Substance Dependence Drug Therapy Adult Analysis of Covariance Australia Brief Symptom Inventory Chi Square Test Cognitive Therapy Confidence Intervals Counseling Data Analysis Software Descriptive Statistics Double-Blind Studies Female Funding Source Immunoassay Interview Guides Interviews Male Mann-Whitney U Test Methamphetamine Middle Age Modafinil Adverse Effects Pretest-Posttest Design Prospective Studies Psychological Tests Scales Self Report Severity of Illness Indices Mass Spectrometry Substance Abuse Detection Survival Analysis T-Tests Treatment Outcomes Urinalysis Visual Analog Scaling Human Adult: 19-44 years Middle Aged: 45-64 years Female Male ab: AIM: To examine the safety and efficacy of modafinil (200 mg/day) compared to placebo in the treatment of methamphetamine dependence and to examine predictors of post-treatment outcome. PARTICIPANTS AND DESIGN: Eighty methamphetamine-dependent subjects in Sydney, Australia were allocated randomly to modafinil (200 mg/day) (n = 38) or placebo (n = 42) under double-blind conditions for 10 weeks with a further 12 weeks post-treatment follow-up. MEASURES: Comprehensive drug use data (urine specimens and self-report) and other health and psychosocial data were collected weekly during treatment and research interviews at baseline, week 10 and week 22. RESULTS: Treatment retention and medication adherence were equivalent between groups. There were no differences in methamphetamine abstinence, craving or severity of dependence. Medication-compliant subjects tended to provide more methamphetamine-negative urine samples over the 10-week treatment period (P = 0.07). Outcomes were better for methamphetamine-dependent subjects with no other substance dependence and those who accessed counselling. There were statistically significant reductions in systolic blood pressure (P = 0.03) and weight gain (P = 0.05) in modafinil-compliant subjects compared to placebo. There were no medication-related serious adverse events. Adverse events were generally mild and consistent with known pharmacological effects. CONCLUSIONS: Modafinil demonstrated promise in reducing methamphetamine use in selected methamphetamine-dependent patients. The study findings support definitive trials of modafinil in larger multi-site trials. pubtype: Academic Journal doctype: clinical trial research tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|